Literature DB >> 29659822

Development and application of CRISPR/Cas9 technologies in genomic editing.

Cui Zhang1, Renfu Quan2, Jinfu Wang1.   

Abstract

Genomic editing to correct disease-causing mutations is a promising approach for the treatment of human diseases. As a simple and programmable nuclease-based genomic editing tool, the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system has substantially improved the ability to make precise changes in the human genome. Rapid development of CRISPR-based technologies in recent years has expanded its application scope and promoted CRISPR-based therapies in preclinical trails. Here, we review the application of the CRISPR system over the last 2 years; including its development and application in base editing, transcription modulation and epigenetic editing, genomic-scale screening, and cell and embryo therapy. Finally, the prospects and challenges related to application of CRISPR/Cas9 technologies are discussed.

Entities:  

Mesh:

Year:  2018        PMID: 29659822     DOI: 10.1093/hmg/ddy120

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  11 in total

Review 1.  Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives.

Authors:  Khosro Jamebozorgi; Eskandar Taghizadeh; Daryoush Rostami; Hosein Pormasoumi; George E Barreto; Seyed Mohammad Gheibi Hayat; Amirhossein Sahebkar
Journal:  Mol Neurobiol       Date:  2018-11-05       Impact factor: 5.590

Review 2.  Enterobacteria and host resistance to infection.

Authors:  Eugene Kang; Alanna Crouse; Lucie Chevallier; Stéphanie M Pontier; Ashwag Alzahrani; Navoun Silué; François-Xavier Campbell-Valois; Xavier Montagutelli; Samantha Gruenheid; Danielle Malo
Journal:  Mamm Genome       Date:  2018-05-21       Impact factor: 2.957

Review 3.  CRISPR-Cas9-Based Technology and Its Relevance to Gene Editing in Parkinson's Disease.

Authors:  Mujeeb Ur Rahman; Muhammad Bilal; Junaid Ali Shah; Ajeet Kaushik; Pierre-Louis Teissedre; Małgorzata Kujawska
Journal:  Pharmaceutics       Date:  2022-06-13       Impact factor: 6.525

4.  Predicting CRISPR/Cas9 Repair Outcomes by Attention-Based Deep Learning Framework.

Authors:  Xiuqin Liu; Shuya Wang; Dongmei Ai
Journal:  Cells       Date:  2022-06-05       Impact factor: 7.666

Review 5.  New approaches to moderate CRISPR-Cas9 activity: Addressing issues of cellular uptake and endosomal escape.

Authors:  Maja van Hees; Sofie Slott; Anders Højgaard Hansen; Heon Seok Kim; Hanlee P Ji; Kira Astakhova
Journal:  Mol Ther       Date:  2021-06-04       Impact factor: 11.454

6.  Genome scale analysis of pathogenic variants targetable for single base editing.

Authors:  Alexander V Lavrov; Georgi G Varenikov; Mikhail Yu Skoblov
Journal:  BMC Med Genomics       Date:  2020-09-18       Impact factor: 3.063

Review 7.  Genomic and Epigenetic Advances in Focal Cortical Dysplasia Types I and II: A Scoping Review.

Authors:  Joana Jesus-Ribeiro; Luís Miguel Pires; João Daniel Melo; Ilda Patrícia Ribeiro; Olinda Rebelo; Francisco Sales; António Freire; Joana Barbosa Melo
Journal:  Front Neurosci       Date:  2021-01-22       Impact factor: 4.677

8.  Combination gene therapy for HIV using a conditional suicidal gene with CCR5 knockout.

Authors:  Tugba Mehmetoglu-Gurbuz; Rose Yeh; Himanshu Garg; Anjali Joshi
Journal:  Virol J       Date:  2021-01-30       Impact factor: 4.099

9.  Clustered Regularly Interspaced Short Palindromic Repeat Analysis of Clonal Complex 17 Serotype III Group B Streptococcus Strains Causing Neonatal Invasive Diseases.

Authors:  Jen-Fu Hsu; Jang-Jih Lu; Chih Lin; Shih-Ming Chu; Lee-Chung Lin; Mei-Yin Lai; Hsuan-Rong Huang; Ming-Chou Chiang; Ming-Horng Tsai
Journal:  Int J Mol Sci       Date:  2021-10-27       Impact factor: 5.923

Review 10.  Mouse Models of Inherited Retinal Degeneration with Photoreceptor Cell Loss.

Authors:  Gayle B Collin; Navdeep Gogna; Bo Chang; Nattaya Damkham; Jai Pinkney; Lillian F Hyde; Lisa Stone; Jürgen K Naggert; Patsy M Nishina; Mark P Krebs
Journal:  Cells       Date:  2020-04-10       Impact factor: 7.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.